Show Nav →
Please include the following statement when referencing the CPTAC Assay Portal
We would like to acknowledge the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) Assay Portal (assays.cancer.gov) for developing assays and establishing criteria for the assays described in this publication.

Overview Data source: UniProt

Official Gene Symbol Other Aliases
SAAL1 N/A
Sequence Length (AA) Molecular Weight (Da)
474 53558
Protein Name
Protein SAAL1
Sources
UniProt
PhosphoSitePlus ®
GeneCards
Human Protein Atlas

Protein Sequence hover to view complete sequence

10 20 30 40 50
MDRNPSPPPP GRDKEEEEEV AGGDCIGSTV YSKHWLFGVL SGLIQIVSPE
60 70 80 90 100
NTKSSSDDEE QLTELDEEME NEICRVWDMS MDEDVALFLQ EFNAPDIFMG
110 120 130 140 150
VLAKSKCPRL REICVGILGN MACFQEICVS ISSDKNLGQV LLHCLYDSDP
160 170 180 190 200
PTLLETSRLL LTCLSQAEVA SVWVERIQEH PAIYDSICFI MSSSTNVDLL
210 220 230 240 250
VKVGEVVDKL FDLDEKLMLE WVRNGAAQPL DQPQEESEEQ PVFRLVPCIL
260 270 280 290 300
EAAKQVRSEN PEWLDVYMHI LQLLTTVDDG IQAIVHCPDT GKDIWNLLFD
310 320 330 340 350
LVCHEFCQSD DPPIILQEQK TVLASVFSVL SAIYASQTEQ EYLKIEKVDL
360 370 380 390 400
PLIDSLIRVL QNMEQCQKKP ENSAESNTEE TKRTDLTQDD FHLKILKDIL
410 420 430 440 450
CEFLSNIFQA LTKETVAQGV KEGQLSKQKC SSAFQNLLPF YSPVVEDFIK
460 470 474
ILREVDKALA DDLEKNFPSL KVQT

Data source: UniProt


Position of Targeted Peptide Analytes Relative to SNPs, Isoforms, and PTMs

Uniprot Database Entry PhosphoSitePlus ®

Click a point on a node
to view detailed assay information below
All other points link out to UniProt



Phosphorylation Acetylation Ubiquitylation Other

loading

Loader

Assay Details for CPTAC-5928 Collapse assay details

Data source: Panorama

Official Gene Symbol
SAAL1
Peptide Sequence
NGAAQPLDQPQEESEEQPVFR
Modification Type
unmodified
Protein - Site of Modification
224
Peptide - Site of Modification
N/A
Peptide Start
224
Peptide End
244
CPTAC ID
CPTAC-5928
Peptide Molecular Mass
2,368.0931
Species
Homo sapiens (Human)
Assay Type
Enrichment MRM
Enrichment Method
peptide immunoaffinity
Matrix
Cell Lysate
Submitting Laboratory
Fred Hutchinson Cancer Research Center
Submitting Lab PI
Amanda Paulovich

Publication

View Details (opens in a new window)

Targeted Mass Spectrometry Enables Quantification of Novel Pharmacodynamic Biomarkers of ATM Kinase Inhibition. Whiteaker JR, Wang T, Zhao L, Schoenherr RM, Kennedy JJ, Voytovich U, Ivey RG, Huang D, Lin C, Colantonio S, Caceres TW, Roberts RR, Knotts JG, Kaczmarczyk JA, Blonder J, Reading JJ, Richardson CW, Hewitt SM, Garcia-Buntley SS, Bocik W, Hiltke T, Rodriguez H, Harrington EA, Barrett JC, Lombardi B, Marco-Casanova P, Pierce AJ, Paulovich AG. Cancers (Basel). 2021 Jul 30;13(15):3843. doi: 10.3390/cancers13153843. PMID: 34359745


Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument
Sciex 5500 QTRAP
Internal Standard
peptide
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N at C-terminus R
LC
Eksigent 425
Column Packing
Reprosil
Column Dimensions
75um x 15cm
Flow Rate
300 nL/min

Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader

Repeatability

Data source: Panorama

  Average intra-assay CV
(within day CV)
Average inter-assay CV
(between day CV)
Total CV
equation
n=
Fragment ion / Transition Low Med High Low Med High Low Med High Low Med High
y5 (1+) 32.1 12.2 9.2 42.5 18.1 11.5 53.3 21.8 14.7 15 27 15
b5 (1+) 31.8 15.1 10.6 41.5 16.7 10.3 52.3 22.5 14.8 15 27 15
y12 (2+) 18.4 16.3 7.5 36.3 17.5 10.5 40.7 23.9 12.9 15 27 15
y4 (1+) 27.5 10 8.1 35 16.2 7.8 44.5 19 11.2 15 27 15
y6 (1+) 46.2 20.3 12.1 53 22.4 13.9 70.3 30.2 18.4 15 27 15
b9 (1+) 53.5 16.5 11 45 20.7 13.2 69.9 26.5 17.2 15 27 15
b8 (1+) 31.7 16.6 13.6 48.9 20.6 14.4 58.3 26.5 19.8 15 27 15
sum 10.1 6.5 4.2 17.2 11.9 4.1 19.9 13.6 5.9 15 27 15


Additional Resources and Comments


Assay Details for CPTAC-5929 Collapse assay details

Data source: Panorama

Official Gene Symbol
SAAL1
Peptide Modified Sequence
NGAAQPLDQPQEES[+79.966331]EEQPVFR
Modification Type
Phospho (ST)
Protein - Site of Modification
238
Peptide - Site of Modification
14
Peptide Start
224
Peptide End
244
CPTAC ID
CPTAC-5929
Peptide Molecular Mass
2,448.0595
Species
Homo sapiens (Human)
Assay Type
Enrichment MRM
Enrichment Method
peptide immunoaffinity
Matrix
Cell Lysate
Submitting Laboratory
Fred Hutchinson Cancer Research Center
Submitting Lab PI
Amanda Paulovich

Publication

View Details (opens in a new window)

Targeted Mass Spectrometry Enables Quantification of Novel Pharmacodynamic Biomarkers of ATM Kinase Inhibition. Whiteaker JR, Wang T, Zhao L, Schoenherr RM, Kennedy JJ, Voytovich U, Ivey RG, Huang D, Lin C, Colantonio S, Caceres TW, Roberts RR, Knotts JG, Kaczmarczyk JA, Blonder J, Reading JJ, Richardson CW, Hewitt SM, Garcia-Buntley SS, Bocik W, Hiltke T, Rodriguez H, Harrington EA, Barrett JC, Lombardi B, Marco-Casanova P, Pierce AJ, Paulovich AG. Cancers (Basel). 2021 Jul 30;13(15):3843. doi: 10.3390/cancers13153843. PMID: 34359745


Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument
Sciex 5500 QTRAP
Internal Standard
peptide
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N at C-terminus R
LC
Eksigent 425
Column Packing
Reprosil
Column Dimensions
75um x 15cm
Flow Rate
300 nL/min

Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader

Repeatability

Data source: Panorama

  Average intra-assay CV
(within day CV)
Average inter-assay CV
(between day CV)
Total CV
equation
n=
Fragment ion / Transition Low Med High Low Med High Low Med High Low Med High
b17 (2+) 46 14 10.7 48.9 17 11.2 67.1 22 15.5 15 27 15
b9 (1+) 29.2 14.6 7.6 33.8 15.4 12.1 44.7 21.2 14.3 15 27 15
b8 (1+) 30.1 17.8 10.8 34.3 20.6 14.5 45.6 27.2 18.1 15 27 15
b5 (1+) 27.7 9.3 5.3 33.7 15.4 11.1 43.6 18 12.3 15 27 15
y12 (2+) 24.7 12.9 12.1 16.3 12.4 16.6 29.6 17.9 20.5 15 27 15
y4 (1+) 23.3 8.7 7.1 20.3 11.2 11.9 30.9 14.2 13.9 15 27 15
y5 (1+) 51.2 19.1 13.5 53.8 19.5 15.6 74.3 27.3 20.6 15 27 15
sum 8.9 4.2 2.7 11.8 8.6 9.1 14.8 9.6 9.5 15 27 15


Additional Resources and Comments